IN THE UNITED STATES PATENT AND TRADEMARK OFFICE [SXAP-00000] (38-000)

In re Application of: RONN, et al

Serial No.: 09/787,443 Filed: July 30, 2001

For: NCAM BINDING COMPOUNDS

Confirmation No.: 6998

MAR 3 1 2004 & TRADEMAR

Art Unit: 1647 Examiner: NICHOLS, C. Washington, D.C. Atty.'s Docket: RONN=1 Date: March 31, 2004

U.S. Patent and Trademark Office 2011 South Clark Place Customer Window, Mail Stop AF

Crystal Plaza Two, Lobby, Room 1B03

Arlington, Virginia 22202

Transmitted herewith is an [] Amendment [XX] Amendment After Final Rejection, Sequence Listing (paper and CRF) in the above-identified application.

- [] Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted.
- Small entity status of this application under 37 CFR 1.9 and 1.27 implicitly by payment of small entit September 5, 2003 and the correctness of that assertion is confirmed herewith.
- [] No additional fee is required.

The fee has been calculated as shown below:

(Col. 1)			(Col. 2)	(Col. 3) Small Entity			Other Than a Small Entity	
	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra	Rate	Additional Fee	Rate	Additional Fee
Total	25	Minus	50	0	x 9	\$	×18	\$
Indep.	1	Minus	3	0	x43	\$	x86	\$
First Presentation of Multiple Dependent Claim 145						\$	+290	\$
TOTAL ADDITIONAL CLAIMS FEE						ş	Total	\$

- If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

 If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.

 If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.
- The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in

Col.1 of a prior amendment of the number of claims originally filed.

Conditional Petition for Extension of Time

If any extension of time for a response is required applicant requests that this be considered a petit

[XX] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity Other Than Small Entity Response Filed Within Response Filed Within [XX] First - \$ 55.00 First - \$ 110.00] Second \$ 210.00 Second - \$ 420.00 ſ 7 F 1 - \$ 950.00 1 Third \$ 475.00 Third ſ Γ 1 Fourth \$ 740.00 ſ } Fourth - \$1480.00 Fifth \$1005.00 Fifth - \$2010.00]

-) already paid for [] Less fees (\$ months extension of time on
- [] Please charge my Deposit Account No. 02-4035 in the amount of \$___ _. A duplicate copy of this sheet is attached.
- [XX] Credit Card Payment Form, PTO-2038, authorizing payment in the amount of \$55.00 is attached.
- [XX] The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR Section 1.16 and all patent processing fees under 37 CFR Section 1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR Section 1.18.

BROWDY AND NEIMARK P.L.L.C. Attorneys for Applicant(s)

By:

COO₽E Registration %0. 28,005

Facsimile: (202) 737-3528 Telephone: (202) 628-5197

Trage IFUAF &

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

RONN, et al.

Serial No.: 09/787,443

Filed: July 30, 2001

For: NCAM BINDING COMPOUNDS

Confirmation No.: 6998

AMENDMENT AFTER FINAL REJECTION

U.S. Patent and Trademark Office 2011 South Clark Place Customer Window, Mail Stop AF Crystal Plaza Two, Lobby, Room 1B03 Arlington, Virginia 22202

Sir:

In response to the office action mailed December 3, 2003, please enter the following amendments and remarks.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Instructions concerning the sequence listing begin on page 5 of this paper.

Remarks begin on page 6 of this paper.

A Sequence Listing is attached following page 11 of this paper.